Aclaris Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Aclaris Therapeutics
ACRS Stock  USD 4.07  0.25  6.54%   
Aclaris Therapeutics financial statements provide useful quarterly and yearly information to potential Aclaris Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aclaris Therapeutics financial statements helps investors assess Aclaris Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aclaris Therapeutics' valuation are summarized below:
Gross Profit
-60 M
Profit Margin
(1.37)
Market Capitalization
290.7 M
Enterprise Value Revenue
6.3534
Revenue
27.1 M
There are over one hundred nineteen available fundamental signals for Aclaris Therapeutics, which can be analyzed over time and compared to other ratios. All traders should validate Aclaris Therapeutics' prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 80.1 M in 2024. Enterprise Value is likely to drop to about 37 M in 2024

Aclaris Therapeutics Total Revenue

32.81 Million

Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 819.9 K, Interest Expense of 3.2 M or Selling General Administrative of 21.3 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0 or PTB Ratio of 0.67. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aclaris Therapeutics Correlation against competitors.
For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Aclaris Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets169.3 M197.4 M127 M
Slightly volatile
Other Current Liabilities2.1 M2.2 M4 M
Slightly volatile
Total Current Liabilities16.3 M31 M12 M
Slightly volatile
Other Liabilities40.4 M38.5 M10.7 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.6 M1.2 M
Slightly volatile
Accounts Payable7.2 M8.9 M5.4 M
Slightly volatile
Cash52.9 M39.9 M40.7 M
Slightly volatile
Non Current Assets Total72 M68.5 M25.1 M
Slightly volatile
Cash And Short Term Investments137.6 M119.1 M103.6 M
Slightly volatile
Common Stock Shares Outstanding38.5 M69.8 M30.4 M
Slightly volatile
Short Term Investments96.3 M79.2 M71.3 M
Slightly volatile
Liabilities And Stockholders Equity169.3 M197.4 M127 M
Slightly volatile
Non Current Liabilities Total8.8 M9.3 M18.4 M
Pretty Stable
Other Current Assets7.2 M9.5 M5.3 M
Slightly volatile
Other Stockholder Equity495.6 M928.1 M363.5 M
Slightly volatile
Total Liabilities36.1 M40.2 M31.1 M
Slightly volatile
Property Plant And Equipment Gross6.1 M5.8 M2.2 M
Slightly volatile
Total Current Assets139.1 M128.9 M104.7 M
Slightly volatile
Property Plant Equipment1.9 M1.3 M1.4 M
Slightly volatile
Other Assets1.9 M2 M22 M
Pretty Stable
Net Receivables283.1 K298 K607.9 K
Pretty Stable
Capital Surpluse553.9 M1 B418.2 M
Slightly volatile
Non Current Liabilities Other13.1 M9.3 M7.4 M
Slightly volatile
Short and Long Term Debt Total404.7 K426 K3.1 M
Pretty Stable
Capital Lease Obligations594.9 K426 K358.3 K
Slightly volatile
Net Invested Capital130.4 M157.2 M189.9 M
Slightly volatile
Short and Long Term Debt113.6 K127.8 K139.2 K
Slightly volatile
Net Working Capital106.7 M97.9 M156.8 M
Slightly volatile
Short Term Debt404.7 K426 K477.6 K
Slightly volatile
Long Term Debt Total10.8 M9.6 M21.4 M
Slightly volatile
Current Deferred Revenue11.9 M22.4 M9.8 M
Slightly volatile

Aclaris Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization819.9 K863 K3 M
Pretty Stable
Selling General Administrative21.3 M31.1 M15.9 M
Slightly volatile
Other Operating Expenses77.2 M128.6 M57.7 M
Slightly volatile
Research Development103.3 M98.4 M39.5 M
Slightly volatile
Total Operating Expenses74.1 M130.8 M55.4 M
Slightly volatile
Interest Income83.2 K93.6 K101.9 K
Slightly volatile
Preferred Stock And Other Adjustments2.1 M2.3 M2.5 M
Slightly volatile
Reconciled Depreciation1.4 M863 K1.1 M
Slightly volatile
Selling And Marketing Expenses242 K254.7 K28.9 M
Slightly volatile
Non Recurring14.8 M16.7 M18.1 M
Slightly volatile

Aclaris Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow28.7 M45.3 M24.9 M
Slightly volatile
Depreciation1.3 M863 K943.1 K
Slightly volatile
End Period Cash Flow30.8 M39.9 M24.5 M
Slightly volatile
Stock Based Compensation13 M20.5 M8.8 M
Slightly volatile
Change To Netincome22 M22.7 M15 M
Slightly volatile
Change To Inventory730.5 K695.8 K317.6 K
Slightly volatile
Issuance Of Capital Stock25.4 M26.7 M84.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.232.3457236
Slightly volatile
Days Sales Outstanding3.313.480867.0347
Slightly volatile
Stock Based Compensation To Revenue0.620.65745.3332
Slightly volatile
Capex To Depreciation1.441.516812.6503
Slightly volatile
EV To Sales1.031.0831168
Slightly volatile
Payables Turnover2.142.03660.576
Slightly volatile
Sales General And Administrative To Revenue0.950.995211.7331
Slightly volatile
Research And Ddevelopement To Revenue2.993.148415.391
Slightly volatile
Capex To Revenue0.03980.04190.4403
Slightly volatile
Cash Per Share1.621.70623.9609
Very volatile
Days Payables Outstanding1701794.4 K
Slightly volatile
Income Quality0.870.88520.8256
Slightly volatile
Intangibles To Total Assets0.00130.00140.0942
Slightly volatile
Net Debt To EBITDA0.320.33561.1184
Slightly volatile
Current Ratio3.954.163120.1643
Slightly volatile
Receivables Turnover11010523.1741
Slightly volatile
Graham Number15.488.013111.9663
Pretty Stable
Debt To Equity0.00260.00270.1048
Slightly volatile
Capex Per Share0.03310.01880.0327
Slightly volatile
Revenue Per Share0.470.44760.1689
Slightly volatile
Interest Debt Per Share0.00580.00610.5712
Slightly volatile
Debt To Assets0.00210.00220.0768
Slightly volatile
Days Of Payables Outstanding1701794.4 K
Slightly volatile
Ebt Per Ebit0.820.91261.0062
Very volatile
Long Term Debt To Capitalization0.140.20.1547
Slightly volatile
Total Debt To Capitalization0.00260.00270.09
Slightly volatile
Debt Equity Ratio0.00260.00270.1048
Slightly volatile
Quick Ratio3.954.163120.3176
Slightly volatile
Net Income Per E B T1.190.99591.0512
Slightly volatile
Cash Ratio1.221.288410.1703
Slightly volatile
Days Of Sales Outstanding3.313.480867.0347
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.01671.0347
Pretty Stable
Fixed Asset Turnover20.2519.28955.7267
Slightly volatile
Debt Ratio0.00210.00220.0768
Slightly volatile
Price Sales Ratio2.232.3457236
Slightly volatile
Asset Turnover0.170.15830.0466
Slightly volatile
Gross Profit Margin0.250.42140.2937
Pretty Stable

Aclaris Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap80.1 M84.3 M261.4 M
Very volatile
Enterprise Value37 M38.9 M224.2 M
Very volatile

Aclaris Fundamental Market Drivers

Cash And Short Term Investments119.1 M

Aclaris Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aclaris Therapeutics Financial Statements

Aclaris Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue22.4 M11.9 M
Total Revenue31.2 M32.8 M
Cost Of Revenue18.1 M19 M
Stock Based Compensation To Revenue 0.66  0.62 
Sales General And Administrative To Revenue 1.00  0.95 
Research And Ddevelopement To Revenue 3.15  2.99 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.45  0.47 
Ebit Per Revenue(3.12)(3.27)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY